Lupus Trials News
July 19,2023 The LRA is pleased to share news announced by Aurinia Pharmaceuticals of published results showing that the lupus...Read More
Project CHANGE Launches Pilot Programs in Atlanta, Nashville, and Philadelphia to Increase Diversity in Lupus Clinical Research
New York, NY. June 29. Lupus Therapeutics, the clinical research affiliate of the Lupus Research Alliance, today announced the launch...Read More
Rituximab biosimilar BCD020 showed effectiveness in treating lupus nephritis in a pediatric population according to results of a retrospective study...Read More
Lupus Therapeutics Partners to Evaluate Potential Treatment for SLE and Lupus Nephritis Through North American Trial Network
NEW YORK, N.Y. — June 2, 2023 Lupus Therapeutics announced the start of a collaboration to conduct three Phase 3...Read More
May 31, 2023 We are pleased to share encouraging news from EULAR, the annual meeting of the European Alliance of...Read More
Lupus Research Alliance Unites the U.S. Food & Drug Administration (FDA) & Lupus Community to Launch Novel Public-Private Partnership
Lupus Accelerating Breakthroughs Consortium to address challenges impacting lupus trial success and to accelerate treatment breakthroughs Washington, DC, March 29,...Read More
NEW YORK, NY. January 17— The Lupus Research Alliance (LRA) is pleased to announce the appointment of Stacie J. Bell,...Read More
Promising Data Shows Lupus Research Alliance Peer Education Program Increases Intentions to Join Clinical Trials Among Diverse Patient Population
ACR Convergence 2022 Included LRA-Authored Research on Measures to Demonstrate Treatment Efficacy for Patients with Lupus NEW YORK, NY–November 8,...Read More
September 21, 2022 Lupkynis® (voclosporin) was just granted marketing authorization in the European Union as a new treatment for adults...Read More
New England Journal of Medicine Publishes Positive Data of Litifilimab in Cutaneous Lupus Erythematosus
August, 2022 We are pleased to share positive results from the two-part Phase 2 LILAC study published in the New England...Read More
NEW YORK, NY. July 27, 2022. The Lupus Research Alliance (LRA) is pleased to share that the U.S. Food and...Read More
July 14, 2022 The booster dose of the SARS-CoV-2 vaccine significantly enhanced the degree of protection from COVID-19 infections for...Read More
Lupus Research Alliance and Lupus Therapeutics Response to Positive Data from Phase 2 Study on Potential First-in-class Lupus Treatment
June 1, 2022 The Lupus Research Alliance (LRA) and its clinical trial arm Lupus Therapeutics congratulate Bristol Myers Squibb (BMS)...Read More
March 24, 2022 Recognized for her contributions to lupus during 2022’s Women’s History Month, Dr. Jane Salmon chose to specialize...Read More
Judith James, MD, PhD Fulfills Childhood Dream to be a Doctor with Outstanding Career in Lupus Treatment and Research
March 14, 2022 Dr. Judith James has wanted to be a doctor since she was four years old. But it...Read More
February 13, 2022 The LRA is pleased to share a recently published paper reporting that the drug, obinutuzumab, showed positive...Read More
January 28, 2022 The Lupus Research Alliance is disappointed that the Phase 3 development program of OLUMIANT® (baricitinib) as a...Read More
Lupus Research Alliance Launches Two Major Initiatives to Increase Participation of Underrepresented Minorities in Lupus Clinical Trials and Research
January 27, 2022 NEW YORK, NY. January 27 — The Lupus Research Alliance (LRA) and its clinical affiliate Lupus Therapeutics...Read More
December 9, 2021 People with lupus can be immunocompromised because of the disease itself or medications that suppress the immune...Read More
December 9, 2021 The LRA is pleased to share positive topline three-year efficacy and safety results reported today by Aurinia...Read More
June 12, 2019 As reported by The Rheumatologist, Dr. Richard Furie provided his perspective on clinical trials in lupus in...
March 1, 2019 Proteins of the immune system, known as type I interferons, are responsible in part for manifestations of...
February 22, 2019 A study published in the peer-reviewed journal Arthritis & Rheumatology found that people with SLE and particularly...
February 22, 2019 Study results published in the peer-reviewed journal PLOS One showed that elements of physical fitness — muscle...
A study just published in Annals of Internal Medicine showed that kidney transplantation reduced deaths due to lupus nephritis— kidney inflammation caused by lupus....
An observational study published in Lupus of people with lupus found that of six factors, stress, depression and pain contributed most to...
A small randomized Phase 1 study published in Arthritis & Rheumatology found that the existing asthma treatment omalizumab (Xolair) may improve lupus...
Source: Idorsia LTD Press Release Idorsia Ltd (SIX: IDIA) announced that the first patient has been enrolled into a multiple-dose study...
A study just published in Clinical and Experimental Rheumatologyfound that exposure to periodontal bacteria on the gums around the teeth can...